Indian AI coding startup Emergent becomes a unicorn with $130M Series C

TechCrunchIndependentCenter6 hr. ago

Indian AI coding startup Emergent has secured $130 million in Series C funding, bringing its post-money valuation to $1.5 billion—a significant increase from its previous $300 million valuation just four months prior. The round was led by Creaegis, with participation from several notable investors including Khosla Ventures, SoftBank’s Vision Fund 2, and Y Combinator. This brings Emergent’s total funding to $230 million. The startup focuses on providing AI-powered coding tools aimed at small businesses and entrepreneurs, competing with firms like Replit, Anthropic, and OpenAI. Emergent reports $120 million in annual run-rate revenue and over 200,000 paying customers, with a growing presence across North America, Europe, and other regions. While the company highlights its strengths in automation and deployment capabilities, it acknowledges challenges in design differentiation. The funds will be used to enhance product development, expand AI functionality, and grow its global operations.

Bias read (Center): The article presents factual information about a technology startup's fundraising and business strategy without overtly favoring any political ideology. It discusses market competition, technological advancements, and business growth without taking a clear stance on political issues or policies. The

TechCrunchIndependentCenter17 hr. ago

OpenAI researcher Miles Wang is reportedly planning to launch a new startup focused on AI-driven drug discovery, potentially valued at $2 billion and seeking $200 million in funding. The startup, which may include other OpenAI researchers, aims to develop AI models that can identify new drug applications and repurpose existing medications. While Wang has disputed the reported funding figures, the announcement highlights growing investor interest in AI applications within life sciences. This follows similar ventures like Chai Discovery, which raised $400 million at a $3.8 billion valuation, and Isomorphic Labs, which secured $2.1 billion in Series B funding. Wang, who joined OpenAI in 2024 after leaving Harvard, contributed to research on automating scientific discovery.

Bias read (Center): The article presents information about a private-sector development in AI drug discovery without overtly endorsing or criticizing specific political ideologies. It reports on market trends, investment activity, and academic background without taking a clear ideological stance. The framing remains ag